Q2 EPS Estimates for Envoy Medical Reduced by HC Wainwright

Envoy Medical, Inc. (NASDAQ:COCH) – Equities researchers at HC Wainwright reduced their Q2 2026 EPS estimates for Envoy Medical in a research report issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Envoy Medical’s Q3 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

A number of other analysts have also recently issued reports on COCH. Zacks Research raised Envoy Medical to a “hold” rating in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Envoy Medical presently has a consensus rating of “Hold” and an average price target of $2.50.

Envoy Medical Price Performance

Shares of COCH opened at $0.76 on Friday. The business’s 50-day moving average is $0.69 and its 200-day moving average is $0.68. The company has a market capitalization of $58.44 million, a price-to-earnings ratio of -0.75 and a beta of 1.88. Envoy Medical has a fifty-two week low of $0.36 and a fifty-two week high of $1.89.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million.

Institutional Investors Weigh In On Envoy Medical

Several hedge funds have recently modified their holdings of COCH. Focus Partners Wealth acquired a new stake in Envoy Medical during the first quarter worth about $276,000. CIBC Bancorp USA Inc. acquired a new position in Envoy Medical in the 3rd quarter valued at approximately $60,000. Geode Capital Management LLC raised its holdings in Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after acquiring an additional 51,813 shares in the last quarter. Finally, DSG Capital Advisors LLC acquired a new position in Envoy Medical in the 1st quarter valued at approximately $416,000. 8.59% of the stock is owned by institutional investors.

Envoy Medical News Roundup

Here are the key news stories impacting Envoy Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Envoy Medical and kept its $2.50 price target, signaling strong upside potential. Benzinga article
• Positive Sentiment: The analyst published new FY2027 and quarterly EPS estimates, forecasting losses that are smaller over time, which suggests improving profitability trends and can support investor sentiment.
• Neutral Sentiment: HC Wainwright’s FY2027 EPS estimate of $(0.19) was better than the current consensus estimate of $(0.30), but the company is still expected to remain unprofitable in the near term.
• Neutral Sentiment: Additional report summaries outlined Q1 2027 EPS of $(0.06), Q2 2027 EPS of $(0.06), Q3 2027 EPS of $(0.05), and Q4 2027 EPS of $(0.03), reinforcing a gradual improvement profile rather than a near-term earnings swing.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.